We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid POC Test for Diagnosis of Preeclampsia Could Prevent Unnecessary Hospitalization

By LabMedica International staff writers
Posted on 16 May 2022

Preeclampsia is a pregnancy disorder that can have devastating effects on the health of the mother and the unborn baby. More...

Affecting 5-8% of all pregnancies, it is a rapidly progressive and potentially deadly condition. A correct diagnosis of the pregnancy disorder is currently time-consuming and, in many cases, inaccurate. Now, a fast and precise point-of-care test for preeclampsia is being developed that would provide diagnostic certainty and at the same time, save healthcare costs.

MOMM Diagnostics (Basel, Switzerland) is developing a rapid test for preeclampsia that would offer unprecedented sensitivity at the point-of-care. MOMM develops high-sensitivity rapid diagnostic tests. Immediate information during pregnancy check-ups will help doctors to optimize treatment, reduce stress and anxiety for expectant mothers, save lives and reduce costs. The rapid test for preeclampsia will be based on the company’s technology that combines the commercial advantage of lateral flow immunoassays, with the sensitivity of ELISA, and reader simplicity similar to blood glucose meters.

Since pregnant women regularly go to medical check-ups, the test can be carried out at the gynecologist without the need to send blood samples to a specialized diagnostics lab. The rapid screening test for preeclampsia will also spare expectant mothers the long wait for lab results. This will save valuable time and enable treatment to be started quickly. By providing diagnostic certainty, the test would also eliminate the possibility of false positive results by conventional tests that can create unnecessary anxiety for pregnant women.

Related Links:
MOMM Diagnostics 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
ESR Analyzer
TEST1 2.0
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.